TMCI
vs
S&P 500
TMCI
S&P 500
Over the past 12 months, TMCI has underperformed S&P 500, delivering a return of -63% compared to the S&P 500's +14% growth.
Stocks Performance
TMCI vs S&P 500
Performance Gap
TMCI vs S&P 500
Performance By Year
TMCI vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Treace Medical Concepts Inc
Glance View
Treace Medical Concepts, Inc. engages in the design, manufacture, and marketing of orthopedic medical devices and biologic solutions. The company is headquartered in Ponte Vedra, Florida and currently employs 248 full-time employees. The company went IPO on 2021-04-23. The firm is focused on strategic product development activities that improve surgical efficiencies and patient outcomes. The firm's proprietary Lapiplasty 3-dimensional (3D) Bunion Correction System, which is a combination of instruments, implants and surgical methods designed to correct all three dimensions of the bunion deformity, address the root cause of the bunion deformity. The Lapiplasty System combines novel surgical approach, the Lapiplasty Procedure, with its procedural instrumentation and single-use implant kits. The Lapiplasty Procedure is designed to rotate the entire metatarsal bone into normal anatomical position in all three dimensions, eliminating the bump and restoring normal anatomy. The Lapiplasty Procedure can be performed in either hospital outpatient or ambulatory surgery center settings. The firm's brands include Lapiplasty, Fast Grafter and Plantar Python.
